Adverse events associated with mTOR inhibition: Results from the A2310 study comparing everolimus and mmf in de novo heart transplant recipients

Poncelet, Alain; Musumeci, F; Fuchs, U; F. Mattei, M; Dong, G; Lopez, P; Hirt, S

doi:10.1111/j.1432-2277.2011.01346.x

Adverse events associated with mTOR inhibition: Results from the A2310 study comparing everolimus and mmf in de novo heart transplant recipients

Poncelet, Alain

;

Musumeci, F

;

Fuchs, U

;

F. Mattei, M

;

Hirt, S

;et.al.

(2011) 15th Congress of the European Society for Organ Transplantation, ESOT and 22nd Annual Conference of the British Society for His — Location: Glasgow, United Kingdom (4.September.2011)

Files

Poncelet-2011-15thcongressofESOT0911.pdf

Open Access
Adobe PDF
47.64 KB

Download

Details

Authors

Poncelet, AlainUCLouvain
Author
Musumeci, F
Author
Fuchs, U
Author
F. Mattei, M
Author
Hirt, S
Author

Affiliations

Citations

APA
Chicago
FWB

Poncelet, A., Musumeci, F., Fuchs, U., F. Mattei, M., Dong, G., Lopez, P., & Hirt, S. (2011). Adverse events associated with mTOR inhibition: Results from the A2310 study comparing everolimus and mmf in de novo heart transplant recipients. Transplant International, 24(Suppl. 2), 58. https://doi.org/10.1111/j.1432-2277.2011.01346.x (Original work published 2011)